Wall Street analyst estimates for Monte Rosa Therapeutics, Inc. (GLUE): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.23 | ||
| 2026-08-06 | $-0.43 | $-0.38 | -13.0% |
| 2026-05-07 | $-0.45 | $-0.28 | -60.7% |
| 2026-03-17 | $-0.54 | $-0.35 | -53.6% |
| 2025-11-06 | $-0.33 | $-0.37 | +9.9% |
| 2025-08-07 | $-0.15 | $-0.38 | +60.2% |
| 2025-05-08 | $0.57 | $-0.00 | +21690.9% |
| 2025-03-20 | $0.23 | $0.02 | +1379.1% |
Valuation Ratios
| Price / Book | 2.38 |
| EV / EBITDA | -7.17 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | $75.6M | $123.7M |
| Cost of Revenue | $72000 | $537000 | 0 | 0 | $6.2M | $8.1M | $8.4M |
| Gross Profit | -$72000 | -$537000 | 0 | 0 | -$6.2M | $67.5M | $115.3M |
| Research & Development | $7.3M | $23.5M | $57.2M | $85.1M | $105.0M | $121.6M | $141.5M |
| Selling, General & Admin | $644000 | $4.0M | $15.7M | $27.3M | $32.0M | $35.2M | $36.4M |
| Operating Expenses | $8.0M | $27.5M | $72.9M | $112.4M | $137.1M | $148.6M | $169.5M |
| Operating Income | -$8.0M | -$28.0M | -$72.9M | -$112.4M | -$143.3M | -$81.1M | -$54.2M |
| EBITDA | -$7.7M | -$27.5M | -$71.8M | -$101.0M | -$128.8M | -$62.0M | -$31.4M |
| Interest Expense | $1000 | 0 | 0 | $3.8M | 0 | 0 | 0 |
| Pre-tax Income | -$7.7M | -$35.9M | -$74.0M | -$108.5M | -$135.0M | -$70.1M | -$39.7M |
| Income Tax | 0 | 0 | 0 | 0 | $338000 | $2.6M | -$1.1M |
| Net Income | -$8.0M | -$35.9M | -$74.0M | -$108.5M | -$135.4M | -$72.7M | -$38.6M |
| EPS | $-0.18 | $-0.82 | $-1.59 | $-2.30 | $-2.63 | $-0.98 | $-0.59 |
| EPS (Diluted) | $-0.18 | $-0.82 | $-1.59 | $-2.30 | $-2.63 | $-0.98 | $-0.59 |
| Shares Outstanding (Diluted) | $44.0M | $44.0M | $46.5M | $47.2M | $51.4M | $73.9M | $65.5M |
Price
| Price | $12.65 |
| Market Cap | $1.1B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ARVN · AVBP · DAWN · DNA · GERN · MGTX · REPL
Explore sector: Healthcare · Biotechnology
More sections of GLUE: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks